Trial Profile
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Anal cancer; Cervical cancer; Condylomata acuminata; Head and neck cancer; Human papillomavirus infections; Vulvovaginal cancer
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 05 Sep 2023 Results (n=1272) assessing immunogenicity and effectiveness through 10 years after the last vaccine dose published in the Pediatrics.
- 05 Sep 2023 According to a Glyscend Therapeutics Media Release, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics.
- 05 Sep 2023 Results presented in a Glyscend Therapeutics Media Release.